Immatics (NASDAQ:IMTX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Immatics (NASDAQ:IMTX) from a hold rating to a sell rating in a report published on Sunday morning.

Several other equities research analysts also recently commented on the company. Leerink Partners restated an “outperform” rating and set a $17.00 price objective on shares of Immatics in a report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research report on Thursday, January 22nd. Guggenheim boosted their price target on shares of Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Immatics in a research note on Monday, November 24th. Finally, Mizuho set a $25.00 price objective on shares of Immatics in a report on Thursday, February 19th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $19.20.

Immatics Price Performance

IMTX stock opened at $9.84 on Friday. The company’s 50-day moving average is $9.90 and its 200-day moving average is $9.13. The stock has a market capitalization of $1.20 billion, a PE ratio of -9.65 and a beta of 1.34. Immatics has a 1 year low of $3.30 and a 1 year high of $12.41.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Bank of America Corp DE grew its position in Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after purchasing an additional 2,231 shares in the last quarter. Quarry LP bought a new position in shares of Immatics during the 4th quarter worth approximately $84,000. Insigneo Advisory Services LLC purchased a new position in shares of Immatics in the 3rd quarter worth approximately $103,000. Fox Run Management L.L.C. bought a new position in shares of Immatics in the fourth quarter valued at approximately $129,000. Finally, Graham Capital Management L.P. bought a new position in shares of Immatics in the fourth quarter valued at approximately $206,000. 64.41% of the stock is owned by institutional investors.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.